Transgene
Developing viral immunotherapies like vaccines and oncolytic viruses to treat solid tumors.
TNG | PA
Overview
Corporate Details
- ISIN(s):
- FR0005175080
- LEI:
- 969500PDJW8N0FSGGK69
- Country:
- France
- Address:
- 400 BOULEVARD GONTHIER D'ANDERNACH, 67400 ILLKIRCH-GRAFFENSTADEN
- Website:
- https://www.transgene.fr/en/
- Sector:
- Mining and quarrying
- Industry:
- Mining of non-ferrous metal ores
Description
Transgene is a clinical-stage biotechnology company that designs and develops immunotherapeutics for the treatment of cancer. The company specializes in creating therapeutic vaccines and oncolytic viruses designed to harness the patient's immune system to fight tumors. Its pipeline is built upon proprietary viral vector technologies, including the invir.IO® platform, which generates innovative multifunctional oncolytic viruses capable of modulating the tumor microenvironment. Transgene's product candidates are being evaluated in clinical trials for various solid tumors, including head and neck cancers and metastatic colorectal cancer.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-09-16 17:45 |
Earnings Release
Données positives de la Phase I randomisée de TG4050, vaccin thérapeutique indi…
|
French | 684.0 KB | ||
| 2025-09-16 17:45 |
Report Publication Announcement
Mise à disposition du Rapport Financier Semestriel au 30 juin 2025
|
French | 209.1 KB | ||
| 2025-09-16 17:45 |
Earnings Release
Transgene’s Individualized Neoantigen Therapeutic Cancer Vaccine TG4050 Deliver…
|
English | 558.3 KB | ||
| 2025-09-16 17:45 |
Report Publication Announcement
Availability of Transgene’s Half-Year Financial Report as of June 30, 2025
|
English | 221.5 KB | ||
| 2025-07-09 17:45 |
Board/Management Information
Transgene nomme une experte de l’industrie pharmaceutique, Emmanuelle Quilès, e…
|
French | 387.4 KB | ||
| 2025-07-09 17:45 |
Board/Management Information
Transgene Appoints Seasoned Industry Executive Emmanuelle Quilès to Board of Di…
|
English | 255.1 KB | ||
| 2025-06-19 08:00 |
Legal Proceedings Report
Transgene Completes Initial Patient Screening in Phase II Part of TG4050 Trial …
|
English | 310.5 KB | ||
| 2025-06-19 08:00 |
Legal Proceedings Report
Transgene finalise la sélection initiale de patients pour la partie Phase II de…
|
French | 304.7 KB | ||
| 2025-06-13 08:30 |
Report Publication Announcement
Transgene participera à plusieurs rencontres avec des acteurs clés de la biotec…
|
French | 304.7 KB | ||
| 2025-06-13 08:30 |
Report Publication Announcement
Transgene to Participate in Upcoming Meetings with Biotech Industry Leaders
|
English | 277.0 KB | ||
| 2025-06-03 08:00 |
Regulatory News Service
Transgene organise un webinaire sur les résultats positifs de TG4050 dans les c…
|
French | 269.2 KB | ||
| 2025-06-03 08:00 |
Report Publication Announcement
Transgene to Host Webcast on Positive TG4050 Head and Neck Cancer Data Presente…
|
English | 282.5 KB | ||
| 2025-06-01 19:15 |
Regulatory News Service
Transgene et NEC présentent une survie sans récidive durable, accompagnée d’une…
|
French | 378.8 KB | ||
| 2025-06-01 19:15 |
Earnings Release
Transgene and NEC Present Durable Disease-Free Survival and Sustained T Cell Re…
|
English | 394.4 KB | ||
| 2025-05-22 17:45 |
Regulatory News Service
Transgene présente des données de survie sans récidive à 24 mois sur l’ensemble…
|
French | 378.1 KB |
Automate Your Workflow. Get a real-time feed of all Transgene filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for Transgene via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-07-30 | N/A | Other | Other | 30,898,876 | 32,999,999.57 EUR |
| 2023-05-26 | N/A | Other | Buy | 29,325 | N/A |
